



- (51) **International Patent Classification:**
C12N 5/0789 (2010.01) C12N 5/0783 (2010.01)
- (21) **International Application Number:**
PCT/US2023/071097
- (22) **International Filing Date:**
27 July 2023 (27.07.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/392,760 27 July 2022 (27.07.2022) US
- (71) **Applicant: UMOJA BIOPHARMA, INC.** [US/US]; 1616 Eastlake Avenue East, Suite 550, Seattle, Washington 98102 (US).
- (72) **Inventors: ROWLAND, Teisha J.**; c/o Umoja Biopharma, Inc., 1616 Eastlake Avenue East, Suite 550, Seattle, Washington 98102 (US). **ARNOLD, Cassidy**; c/o Umoja Biopharma, Inc., 1616 Eastlake Avenue East, Suite 550, Seattle, Washington 98102 (US). **YINGST, Ashley M.**; c/o Umoja Biopharma, Inc., 1616 Eastlake Avenue East, Suite 550, Seattle, Washington 98102 (US). **O'HARA, Samantha**; c/o Umoja Biopharma, Inc., 1616 Eastlake Avenue East, Suite

550, Seattle, Washington 98102 (US). **JARRELL, Dillon**; c/o Umoja Biopharma, Inc., 1616 Eastlake Avenue East, Suite 550, Seattle, Washington 98102 (US). **VERIEDE, David T.**; c/o Umoja Biopharma, Inc., 1616 Eastlake Avenue East, Suite 550, Seattle, Washington 98102 (US). **KONING, Ryan**; c/o Umoja Biopharma, Inc., 1616 Eastlake Avenue East, Suite 550, Seattle, Washington 98102 (US).

- (74) **Agent: HARRIS, Ariana D.** et al.; 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004-2400 (US).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (54) **Title:** DIFFERENTIATION OF STEM CELLS IN SUSPENSION CULTURE




FIG. 1

- (57) **Abstract:** Provided are xenogenic-free methods and compositions for generating hematopoietic progenitors and natural killer (NK) cells in 3D suspension culture.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*